Search Results - "Sirotinsky, E"

Fibrosis assessment in patients with nonalcoholic fatty liver disease: Adherence to proposed algorithms and barriers to complying with them by Marciano, S., Dirchwolf, M., Torres, M.C., Allevato, J., García Dans, C., García, B., Pollarsky, F., Gaite, L., Sirotinsky, E., Rios, B., Anselmo, M.N., Peche, M., Hurtado, E., Haddad, L., Narvaez, A., Mauro, E., Martinez, A., Bellizzi, C., Ratusnu, N., D’Amico, C., Arora, S., Gadano, A.

“…Fibrosis staging in patients with nonalcoholic fatty liver disease (NAFLD) is carried out through the application of stepwise algorithms but there is little…”
Get full text

Fibrosis assessment in patients with nonalcoholic fatty liver disease: Adherence to proposed algorithms and barriers to complying with them by Marciano, S, Dirchwolf, M, Torres, M C, Allevato, J, García Dans, C, García, B, Pollarsky, F, Gaite, L, Sirotinsky, E, Rios, B, Anselmo, M N, Peche, M, Hurtado, E, Haddad, L, Narvaez, A, Mauro, E, Martinez, A, Bellizzi, C, Ratusnu, N, D Amico, C, Arora, S, Gadano, A

“…Fibrosis staging in patients with nonalcoholic fatty liver disease (NAFLD) is carried out through the application of stepwise algorithms but there is little…”
Get full text

Pre-treatment prediction of response to peginterferon plus ribavirin in chronic hepatitis C genotype 3 by Marciano, Sebastián, Borzi, Silvia M, Dirchwolf, Melisa, Ridruejo, Ezequiel, Mendizabal, Manuel, Bessone, Fernando, Sirotinsky, María E, Giunta, Diego H, Trinks, Julieta, Olivera, Pablo A, Galdame, Omar A, Silva, Marcelo O, Fainboim, Hugo A, Gadano, Adrián C

“…To evaluate pre-treatment factors associated with sustained virological response (SVR) in patients with hepatitis C virus (HCV) genotype 3 treated with…”
Get full text

Evaluación de fibrosis en pacientes con enfermedad por hígado graso no alcohólico: adherencia a los algoritmos propuestos y barreras para cumplir con ellos by Marciano, S., Dirchwolf, M., Torres, M.C., Allevato, J., García Dans, C., García, B., Pollarsky, F., Gaite, L., Sirotinsky, E., Rios, B., Anselmo, M.N., Peche, M., Hurtado, E., Haddad, L., Narvaez, A., Mauro, E., Martinez, A., Bellizzi, C., Ratusnu, N., D́Amico, C., Arora, S., Gadano, A.

“…La estadificación de la fibrosis en pacientes con enfermedad por hígado graso no alcohólico (EHGNA) se realiza aplicando distintos algoritmos. Sin embargo, hay…”
Get full text

Access to direct-acting antivirals for the treatment of hepatitis C in a country with limited resources by Marciano, S, Haddad, L, Borzi, S M, D'Amico, C, Gaite, L A, Aubone, M V, Sirotinsky, M E, Ratusnu, N, Frola, M S, Aparicio, M C, Ríos, B, Anselmo, M N, Hansen, R, De Filippi, S, Dans, C García, de Labra, L, Peche, M A, Strella, T M, Ibáñez Duran, M, García Rosales, M B, Dirchwolf, M, Galdame, O A, Gadano, A C

“…To estimate the proportion of patients who access to direct-acting antivirals agents (DAAs) for the treatment of hepatitisC in Argentina and to evaluate…”
Get full text

Pre-treatment prediction of response to peginterferon plusribavirin in chronic hepatitis C genotype 3 by Sebastián Marciano Silvia M Borzi Melisa Dirchwolf Ezequiel Ridruejo Manuel Mendizabal Fernando Bessone María E Sirotinsky Diego H Giunta Julieta Trinks Pablo A Olivera Omar A Galdame Marcelo OSilva Hugo A Fainboim Adrián C Gadano

“…AIM： To evaluate pre-treatment factors associatedwith sustained virological response （SVR） in patientswith hepatitis C virus （HCV） genotype 3 treated…”
Get full text